# Avista Corp: financial statements, quarterly

AVA · NYSE · CIK 104918 · [Utilities](/sectors/utilities.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ava.md) · [Financials](/companies/ava/financials.md) · [Filings](/companies/ava/filings.md) · [Insiders](/companies/ava/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ava/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [380](/filings/0000950170-24-121737.md) | [518 d](/filings/0001193125-26-067872.md) | [609](/filings/0000950170-25-064737.md) | [402](/filings/0000950170-25-103360.md) | [394](/filings/0001193125-25-265351.md) | [533 d](/filings/0001193125-26-067872.md) | [617](/filings/0001193125-26-204658.md) | [411](/filings/0001193125-26-329083.md) | [403](/filings/0001193125-25-265351.md) | [533 d](/filings/0001193125-26-067872.md) | [570](/filings/0001193125-26-204658.md) | [413](/filings/0001193125-26-329083.md) |
| Operating income | $m | [38.1](/filings/0000950170-24-121737.md) | [99.5 d](/filings/0001193125-26-067872.md) | [101](/filings/0000950170-25-064737.md) | [55.0](/filings/0000950170-25-103360.md) | [49.0](/filings/0001193125-25-265351.md) | [102 d](/filings/0001193125-26-067872.md) | [125](/filings/0001193125-26-204658.md) | [57.0](/filings/0001193125-26-329083.md) | [60.0](/filings/0001193125-25-265351.md) | [112 d](/filings/0001193125-26-067872.md) | [134](/filings/0001193125-26-204658.md) | [54.0](/filings/0001193125-26-329083.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(3.8)](/filings/0000950170-24-121737.md) | [(17.8) d](/filings/0001193125-26-067872.md) | [2.0](/filings/0000950170-25-064737.md) | [1.0](/filings/0000950170-25-103360.md) | [0.0](/filings/0001193125-25-265351.md) | [1.0 d](/filings/0001193125-26-067872.md) | [12.0](/filings/0001193125-26-204658.md) | [1.0](/filings/0001193125-26-329083.md) | [2.0](/filings/0001193125-25-265351.md) | [9.0 d](/filings/0001193125-26-067872.md) | [13.0](/filings/0001193125-26-204658.md) | [6.0](/filings/0001193125-26-329083.md) |
| Net income | $m | [14.7](/filings/0000950170-24-121737.md) | [84.0 d](/filings/0001193125-26-067872.md) | [71.0](/filings/0000950170-25-064737.md) | [23.0](/filings/0000950170-25-103360.md) | [18.0](/filings/0001193125-25-265351.md) | [67.0 d](/filings/0001193125-26-067872.md) | [79.0](/filings/0001193125-26-204658.md) | [14.0](/filings/0001193125-26-329083.md) | [29.0](/filings/0001193125-25-265351.md) | [71.0 d](/filings/0001193125-26-067872.md) | [92.0](/filings/0001193125-26-204658.md) | [35.0](/filings/0001193125-26-329083.md) |
| Diluted EPS | $ per share | [0.19](/filings/0000950170-24-121737.md) | not reported | [0.91](/filings/0000950170-25-064737.md) | [0.29](/filings/0000950170-25-103360.md) | [0.23](/filings/0001193125-25-265351.md) | not reported | [0.98](/filings/0001193125-26-204658.md) | [0.17](/filings/0001193125-26-329083.md) | [0.36](/filings/0001193125-25-265351.md) | not reported | [1.11](/filings/0001193125-26-204658.md) | [0.43](/filings/0001193125-26-329083.md) |
| Basic EPS | $ per share | [0.19](/filings/0000950170-24-121737.md) | not reported | [0.91](/filings/0000950170-25-064737.md) | [0.29](/filings/0000950170-25-103360.md) | [0.23](/filings/0001193125-25-265351.md) | not reported | [0.98](/filings/0001193125-26-204658.md) | [0.17](/filings/0001193125-26-329083.md) | [0.36](/filings/0001193125-25-265351.md) | not reported | [1.11](/filings/0001193125-26-204658.md) | [0.43](/filings/0001193125-26-329083.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.6](/filings/0000950170-23-057042.md) | [35.0](/filings/0000950170-25-027077.md) | [12.3](/filings/0000950170-24-050788.md) | [14.6](/filings/0000950170-24-092162.md) | [9.1](/filings/0000950170-24-121737.md) | [30.0](/filings/0001193125-26-067872.md) | [17.0](/filings/0000950170-25-064737.md) | [9.0](/filings/0000950170-25-103360.md) | [44.0](/filings/0001193125-25-265351.md) | [19.0](/filings/0001193125-26-329083.md) | [18.0](/filings/0001193125-26-204658.md) | [25.0](/filings/0001193125-26-329083.md) |
| Current assets | $m | [547](/filings/0000950170-23-057042.md) | [662](/filings/0000950170-25-027077.md) | [562](/filings/0000950170-24-050788.md) | [551](/filings/0000950170-24-092162.md) | [525](/filings/0000950170-24-121737.md) | [656](/filings/0001193125-26-067872.md) | [667](/filings/0000950170-25-064737.md) | [667](/filings/0000950170-25-103360.md) | [665](/filings/0001193125-25-265351.md) | [729](/filings/0001193125-26-329083.md) | [735](/filings/0001193125-26-204658.md) | [715](/filings/0001193125-26-329083.md) |
| Total assets | $m | [7,470](/filings/0000950170-23-057042.md) | [7,702](/filings/0001193125-26-067872.md) | [7,649](/filings/0000950170-24-050788.md) | [7,684](/filings/0000950170-24-092162.md) | [7,781](/filings/0000950170-24-121737.md) | [7,941](/filings/0001193125-26-067872.md) | [7,966](/filings/0000950170-25-064737.md) | [8,065](/filings/0000950170-25-103360.md) | [8,162](/filings/0001193125-25-265351.md) | [8,359](/filings/0001193125-26-329083.md) | [8,408](/filings/0001193125-26-204658.md) | [8,535](/filings/0001193125-26-329083.md) |
| Current liabilities | $m | [583](/filings/0000950170-23-057042.md) | [775](/filings/0000950170-25-027077.md) | [580](/filings/0000950170-24-050788.md) | [625](/filings/0000950170-24-092162.md) | [700](/filings/0000950170-24-121737.md) | [771](/filings/0001193125-26-067872.md) | [721](/filings/0000950170-25-064737.md) | [668](/filings/0000950170-25-103360.md) | [729](/filings/0001193125-25-265351.md) | [878](/filings/0001193125-26-329083.md) | [820](/filings/0001193125-26-204658.md) | [650](/filings/0001193125-26-329083.md) |
| Total liabilities | $m | [5,060](/filings/0000950170-23-057042.md) | [5,217](/filings/0000950170-25-027077.md) | [5,128](/filings/0000950170-24-050788.md) | [5,157](/filings/0000950170-24-092162.md) | [5,253](/filings/0000950170-24-121737.md) | [5,350](/filings/0001193125-26-067872.md) | [5,317](/filings/0000950170-25-064737.md) | [5,420](/filings/0000950170-25-103360.md) | [5,517](/filings/0001193125-25-265351.md) | [5,650](/filings/0001193125-26-329083.md) | [5,632](/filings/0001193125-26-204658.md) | [5,714](/filings/0001193125-26-329083.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [15.0](/filings/0000950170-25-027077.md) | [15.0](/filings/0000950170-24-050788.md) | [15.0](/filings/0000950170-24-092162.md) | [15.0](/filings/0000950170-24-121737.md) | [0.0](/filings/0000950170-25-027077.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [222](/filings/0000950170-23-057042.md) | [349](/filings/0000950170-25-027077.md) | [212](/filings/0000950170-24-050788.md) | [244](/filings/0000950170-24-092162.md) | [287](/filings/0000950170-24-121737.md) | [354](/filings/0001193125-26-067872.md) | [287](/filings/0000950170-25-064737.md) | [270](/filings/0000950170-25-103360.md) | [287](/filings/0001193125-25-265351.md) | [388](/filings/0001193125-26-329083.md) | [385](/filings/0001193125-26-204658.md) | [226](/filings/0001193125-26-329083.md) |
| Shareholders' equity | $m | [2,410](/filings/0000950170-24-121737.md) | [2,485](/filings/0001193125-26-067872.md) | [2,520](/filings/0000950170-25-064737.md) | [2,527](/filings/0000950170-25-103360.md) | [2,528](/filings/0001193125-25-265351.md) | [2,591](/filings/0001193125-26-067872.md) | [2,649](/filings/0001193125-26-204658.md) | [2,645](/filings/0001193125-26-329083.md) | [2,645](/filings/0001193125-25-265351.md) | [2,709](/filings/0001193125-26-329083.md) | [2,776](/filings/0001193125-26-204658.md) | [2,821](/filings/0001193125-26-329083.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [124 d](/filings/0000950170-24-121737.md) | [53.7 d](/filings/0001193125-26-067872.md) | [190](/filings/0000950170-25-064737.md) | [127 d](/filings/0000950170-25-103360.md) | [127 d](/filings/0001193125-25-265351.md) | [90.0 d](/filings/0001193125-26-067872.md) | [184](/filings/0001193125-26-204658.md) | [40.0 d](/filings/0001193125-26-329083.md) | [170 d](/filings/0001193125-25-265351.md) | [75.0 d](/filings/0001193125-26-067872.md) | [179](/filings/0001193125-26-204658.md) | [122 d](/filings/0001193125-26-329083.md) |
| Capital expenditure | $m | [133 d](/filings/0000950170-24-121737.md) | [140 d](/filings/0001193125-26-067872.md) | [119](/filings/0000950170-25-064737.md) | [132 d](/filings/0000950170-25-103360.md) | [154 d](/filings/0001193125-25-265351.md) | [128 d](/filings/0001193125-26-067872.md) | [103](/filings/0001193125-26-204658.md) | [143 d](/filings/0001193125-26-329083.md) | [133 d](/filings/0001193125-25-265351.md) | [191 d](/filings/0001193125-26-067872.md) | [150](/filings/0001193125-26-204658.md) | [176 d](/filings/0001193125-26-329083.md) |
| Dividends paid | $m | [35.2 d](/filings/0000950170-24-121737.md) | [35.8 d](/filings/0001193125-26-067872.md) | [38.0](/filings/0000950170-25-064737.md) | [37.0 d](/filings/0000950170-25-103360.md) | [37.0 d](/filings/0001193125-25-265351.md) | [38.0 d](/filings/0001193125-26-067872.md) | [40.0](/filings/0001193125-26-204658.md) | [39.0 d](/filings/0001193125-26-329083.md) | [40.0 d](/filings/0001193125-25-265351.md) | [40.0 d](/filings/0001193125-26-067872.md) | [41.0](/filings/0001193125-26-204658.md) | [40.0 d](/filings/0001193125-26-329083.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [73.3](/filings/0000950170-23-057042.md) | [75.3](/filings/0000950170-24-050788.md) | [76.1](/filings/0000950170-24-092162.md) | [76.8](/filings/0000950170-24-121737.md) | [78.2](/filings/0000950170-25-064737.md) | [78.5](/filings/0000950170-25-103360.md) | [79.0](/filings/0001193125-25-265351.md) | [80.3](/filings/0001193125-26-204658.md) | [80.8](/filings/0001193125-26-329083.md) | [81.3](/filings/0001193125-25-265351.md) | [82.4](/filings/0001193125-26-204658.md) | [83.1](/filings/0001193125-26-329083.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 83,752,830 at 2026-07-24, from the cover of the [10-Q filed 2026-08-03](/filings/0001193125-26-329083.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.